Entera Bio Ltd (ENTX) saw an uptrend of 11.64% in the recent trading with $1.63 being its most recent. The current price level -49.38% lower than the highest price of $3.22 marked by the stock while trading over the past 52-weeks, whereas it is 12.41% higher than the lowest price of $1.45 the company dropped to over past 52-weeks. The latest news story on ENTX appeared in (GlobeNewswire) under the title “Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Entera Bio Ltd Earnings – What Happened With ENTX
Coming around sales and income figures on ENTX Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Entera Bio Ltd (ENTX) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of 25.00% for net revenue.
ENTX – Entera Bio Ltd Stock Earnings Estimates
The perspective of Entera Bio Ltd (NASDAQ:ENTX)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.08 for stock’s EPS in the current quarter. Entera Bio Ltd (ENTX) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of 25.00% for net revenue. Company’s EPS for the last quarter was -0.06.
Entera Bio Ltd – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 45.66 million. ENTX does have institutional investors; and they hold 20.05% of the stock.
As on 2024-06-30, KNOLL CAPITAL MANAGEMENT, LLC was the top most holder in Entera Bio Ltd (NASDAQ:ENTX) with an ownership of 3.88 million shares of the company or 10.5671 of the stake worth $7.14 million. The filing also reveals SCHONFELD STRATEGIC ADVISORS LLC as the second largest holder in the company with a control over 1.8286 of the outstanding shares. Its stake is worth $1.24 million for having 0.67 million shares in hand.
PARKMAN HEALTHCARE PARTNERS LLC also came holding a key position in the company during the recent quarter and it now holds 1.093 of the outstanding shares. With this there are now 22.0 institutions which have possession in ENTX’s shares.
Key Metrics for ENTX
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Entera Bio Ltd has a debt to equity ratio of 0.01.
